NASDAQ$PIII
P3 Health Partners Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
P3 Health Partners' Q3 2023 financial results were announced, showing continued business improvement with key metrics tracking as expected.
P3 Health Partners reported a 16% increase in total revenue to $288.4 million for the third quarter of 2023, with a net loss of $37.3 million. The company reaffirmed its full-year 2023 guidance and provided preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million.
- Total revenue increased by 16% to $288.4 million compared to the third quarter of the prior year.
- Net loss decreased by approximately 43% to $37.3 million compared to the third quarter of the prior year.
- Adjusted EBITDA loss was $22.3 million, compared to an Adjusted EBITDA loss of $40.3 million in the third quarter of the prior year.
- Gross profit was $9.1 million, compared to negative $6.5 million in the prior year.
Headline financials
Revenue & EPS history
P3 Health · Revenue · Quarterly
$288M
Revenue by segment
P3 Health · $386M total across 2 segments · Q1 2026
- Capitated Revenue$379M—98.2%
- Other Revenue$6.89M—1.8%
Forward guidance
The company reaffirmed its full-year 2023 guidance and provided preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2023
-3.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
-2.0%
Avg return
30 days after
37%
7 / 19 earnings
Positive
+11.2%
Q1 2026
Best reaction
-36.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.7% | -9.7% | — | |
| Q1 2026 | +11.2% | +194.4% | +239.9% | |
| Q3 2025 | +0.4% | -12.6% | -25.9% | |
| Q2 2025 | -2.5% | +5.4% | +23.9% | |
| Q1 2025 | -0.6% | -5.9% | -19.5% | |
| Q4 2024 | -4.5% | +1.1% | -1.2% | |
| Q3 2024 | -36.8% | -42.2% | -46.0% | |
| Q2 2024 | -2.5% | -8.7% | -24.1% | |
| Q1 2024 | +2.6% | -11.8% | -21.6% | |
| Q4 2023 | -13.3% | -22.4% | -56.3% | |
| Q4 2021 | +3.1% | -7.6% | -12.2% | |
| Q3 2023 | -2.1% | -8.8% | -19.0% | |
| Q2 2023 | +0.9% | -10.8% | -5.0% | |
| Q4 2022 | -5.9% | -12.7% | +15.5% | |
| Q3 2022 | -11.8% | -19.7% | -33.5% | |
| Q1 2022 | -5.9% | +2.1% | -16.8% | |
| Q2 2022 | -4.1% | +0.6% | -14.0% | |
| Q3 2021 | +0.1% | +0.3% | -19.9% | |
| Q2 2021 | -0.7% | -0.2% | +0.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro